Bull Flag Stocks
PRTA is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
PROTHENA CORP PLC (PRTA) Stock Price & Overview
NASDAQ:PRTA • IE00B91XRN20
Current stock price
10.71 USD
-0.04 (-0.37%)
Last:
The current stock price of PRTA is 10.71 USD. Today PRTA is down by -0.37%. In the past month the price increased by 12.92%. In the past year, price increased by 10.82%.
PRTA Key Statistics
52-Week Range4.32 - 11.69
Current PRTA stock price positioned within its 52-week range.
1-Month Range9.11 - 11.07
Current PRTA stock price positioned within its 1-month range.
- Market Cap
- 576.519M
- P/E
- N/A
- Fwd P/E
- 41.37
- EPS (TTM)
- -3.93
- Dividend Yield
- N/A
PRTA Stock Performance
Today
-0.37%
1 Week
-1.38%
1 Month
+12.92%
3 Months
+7.50%
Longer-term
6 Months +9.47%
1 Year +10.82%
2 Years -47.15%
3 Years -79.57%
5 Years -59.50%
10 Years -75.11%
PRTA Stock Chart
PRTA Stock Screens
PRTA currently appears in the following ChartMill screener lists.
PRTA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRTA. When comparing the yearly performance of all stocks, PRTA turns out to be only a medium performer in the overall market: it outperformed 55.37% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PRTA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRTA. While PRTA has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PRTA Earnings
On February 19, 2026 PRTA reported an EPS of -0.4 and a revenue of 21.00K. The company beat EPS expectations (29.83% surprise) and missed revenue expectations (-98.52% surprise).
Next Earnings DateMay 13, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-$0.40
Revenue Reported21K
EPS Surprise 29.83%
Revenue Surprise -98.52%
PRTA Forecast & Estimates
12 analysts have analysed PRTA and the average price target is 21.42 USD. This implies a price increase of 100% is expected in the next year compared to the current price of 10.71.
For the next year, analysts expect an EPS growth of 106.59% and a revenue growth 939.71% for PRTA
Analysts
Analysts75
Price Target21.42 (100%)
EPS Next Y106.59%
Revenue Next Year939.71%
PRTA Groups
Sector & Classification
PRTA Financial Highlights
Over the last trailing twelve months PRTA reported a non-GAAP Earnings per Share(EPS) of -3.93. The EPS decreased by -70.87% compared to the year before.
Income Statements
Revenue(TTM)9.68M
Net Income(TTM)-244.09M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.69% | ||
| ROE | -87.03% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%62.96%
Sales Q2Q%-99.01%
EPS 1Y (TTM)-70.87%
Revenue 1Y (TTM)-92.83%
PRTA Ownership
Ownership
Inst Owners88.88%
Shares53.83M
Float43.33M
Ins Owners19.38%
Short Float %16.17%
Short Ratio13.76
PRTA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.48 | 351.47B | ||
| AMGN | AMGEN INC | 15.2 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.2 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.75 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.58 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.44 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRTA
Company Profile
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Company Info
IPO: 2012-12-21
PROTHENA CORP PLC
77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60 IE
CEO: Gene G. Kinney
Employees: 67
Phone: 35312362500
PROTHENA CORP PLC / PRTA FAQ
What does PROTHENA CORP PLC do?
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
What is the current price of PRTA stock?
The current stock price of PRTA is 10.71 USD. The price decreased by -0.37% in the last trading session.
Does PROTHENA CORP PLC pay dividends?
PRTA does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRTA stock?
PRTA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is PROTHENA CORP PLC (PRTA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRTA.
Can you provide the upcoming earnings date for PROTHENA CORP PLC?
PROTHENA CORP PLC (PRTA) will report earnings on 2026-05-13.
What is the Short Interest ratio of PROTHENA CORP PLC (PRTA) stock?
The outstanding short interest for PROTHENA CORP PLC (PRTA) is 16.17% of its float.